Total Payments
$10,017
2023 Payments
$104.14
Companies
38
Transactions
648
Medicare Patients
2,241
Medicare Billing
$264,497
Payment Breakdown by Category
Food & Beverage$9,938 (99.2%)
Gifts$53.32 (0.5%)
Education$24.72 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,938 | 644 | 99.2% |
| Gift | $53.32 | 1 | 0.5% |
| Education | $24.72 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,176 | 173 | $0 (2022) |
| ABBVIE INC. | $1,890 | 99 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $786.72 | 65 | $0 (2022) |
| Gilead Sciences, Inc. | $542.42 | 45 | $0 (2022) |
| PFIZER INC. | $385.84 | 23 | $0 (2022) |
| UCB, Inc. | $372.78 | 16 | $0 (2019) |
| Celgene Corporation | $366.21 | 26 | $0 (2022) |
| Janssen Biotech, Inc. | $350.22 | 23 | $0 (2022) |
| Synergy Pharmaceuticals Inc | $347.58 | 12 | $0 (2018) |
| Allergan Inc. | $312.78 | 26 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $104.14 | 1 | ABBVIE INC. ($104.14) |
| 2022 | $1,990 | 127 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($511.53) |
| 2021 | $2,163 | 127 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($663.71) |
| 2020 | $772.01 | 45 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($277.18) |
| 2019 | $2,239 | 153 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($517.78) |
| 2018 | $1,719 | 114 | Synergy Pharmaceuticals Inc ($322.46) |
| 2017 | $1,028 | 81 | AbbVie, Inc. ($201.01) |
All Payment Transactions
648 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/02/2023 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $104.14 | General |
| 11/30/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Gastroenterology | ||||||
| 11/30/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: Gastroenterology | ||||||
| 10/26/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Gastroenterology | ||||||
| 10/19/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: Gastroenterology | ||||||
| 10/13/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $9.97 | General |
| Category: IMMUNOLOGY | ||||||
| 10/12/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: Gastroenterology | ||||||
| 10/12/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Gastroenterology | ||||||
| 10/12/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Neuroscience | ||||||
| 10/11/2022 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/06/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.01 | General |
| Category: Neuroscience | ||||||
| 10/04/2022 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 09/29/2022 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/28/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Gastroenterology | ||||||
| 09/28/2022 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/28/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Gastroenterology | ||||||
| 09/28/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.40 | General |
| Category: Gastroenterology | ||||||
| 09/21/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.58 | General |
| Category: Neuroscience | ||||||
| 09/20/2022 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $20.40 | General |
| Category: GI | ||||||
| 09/20/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/15/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: IMMUNOLOGY | ||||||
| 09/14/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: Immunology | ||||||
| 09/14/2022 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/13/2022 | INTRA-SANA LABORATORIES | RELTONE 200 MG (Drug), RELTONE 400 MG | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Gallstones | ||||||
| 09/13/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 10 | 681 | 730 | $347,195 | $82,031 |
| 2021 | 11 | 916 | 984 | $486,060 | $114,227 |
| 2020 | 12 | 644 | 674 | $238,224 | $68,239 |
Total Patients
2,241
Total Services
2,388
Medicare Billing
$264,497
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 202 | 240 | $64,800 | $24,138 | 37.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 68 | 68 | $51,000 | $13,363 | 26.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 96 | 96 | $84,000 | $13,184 | 15.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 37 | 37 | $37,925 | $7,979 | 21.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 113 | $20,905 | $7,405 | 35.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 83 | 83 | $53,535 | $6,957 | 13.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $22,550 | $6,649 | 29.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $6,360 | $953.29 | 15.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,970 | $925.40 | 31.2% |
| 43450 | Dilation of esophagus | Facility | 2022 | 15 | 15 | $3,150 | $477.96 | 15.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 240 | 290 | $78,300 | $27,105 | 34.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 94 | 94 | $70,500 | $18,902 | 26.8% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 137 | 140 | $90,300 | $12,547 | 13.9% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 85 | 85 | $74,375 | $12,020 | 16.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 99 | 99 | $40,590 | $11,623 | 28.6% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 51 | 51 | $52,275 | $11,103 | 21.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 83 | 98 | $18,130 | $6,736 | 37.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 28 | 28 | $21,000 | $5,339 | 25.4% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 31 | 31 | $23,250 | $4,204 | 18.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 51 | 51 | $13,770 | $4,026 | 29.2% |
| 43450 | Dilation of esophagus unguided | Facility | 2021 | 17 | 17 | $3,570 | $620.45 | 17.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2020 | 70 | 70 | $40,381 | $14,460 | 35.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 108 | 122 | $22,638 | $9,735 | 43.0% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 64 | 64 | $46,572 | $9,127 | 19.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 142 | 154 | $19,566 | $8,224 | 42.0% |
About Dr. Michael Pawlowsky, DO
Dr. Michael Pawlowsky, DO is a Gastroenterology healthcare provider based in Pottstown, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649250416.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Pawlowsky, DO has received a total of $10,017 in payments from pharmaceutical and medical device companies, with $104.14 received in 2023. These payments were reported across 648 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($9,938).
As a Medicare-enrolled provider, Pawlowsky has provided services to 2,241 Medicare beneficiaries, totaling 2,388 services with total Medicare billing of $264,497. Data is available for 3 years (2020–2022), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Pottstown, PA
- Active Since 01/18/2006
- Last Updated 12/17/2019
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1649250416
Products in Payments
- XIFAXAN (Drug) $1,715
- ZEPOSIA (Drug) $523.05
- Cimzia (Drug) $372.78
- Entyvio (Biological) $352.60
- MAVYRET (Drug) $351.22
- Trulance (Drug) $347.58
- Mulpleta (Drug) $306.44
- XELJANZ (Drug) $292.80
- VIBERZI (Drug) $257.45
- STELARA (Biological) $252.13
- LINZESS (Drug) $250.05
- OCALIVA (Drug) $241.93
- Mavyret (Drug) $239.44
- Creon (Drug) $226.21
- ZENPEP (Drug) $217.69
- TRULANCE (Drug) $209.68
- CREON (Drug) $199.86
- DIFICID (Drug) $180.10
- ENTYVIO (Biological) $165.96
- Linzess (Drug) $150.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.